2Birgeggtrd G. Managing anemia in lymphoma and multiple myeloma. Ther Clin Risk Manag,2008,4:527-539.
3Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008, 111:2962 -2972.
4Caravita T, Siniscalchi A, Montanaro M, et al. High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients. Int J Hematol,2009,90:270-272.
5Silvestris F, Cafforio P, Tucci M, et al. Negative regulation of eirthroblast maturation by Fas-L ( + )/TRAIL ( + ) highly malignant plasma cells : a major pathogenetic mechanism of anemia in muhiple myeloma. Blood,2002, 99 : 1305-1313.
6Silvestris F, Tucci M, Cafforio P, et al. Fas-L up-regulation by highly malignant myeloma plasma cells : role in the pathogenesis of anemia and disease progression. Blood, 2001,97:1155-1164.
7Cucuianu A, Patiu M, Rusu A, et al. Hepcidin and multiple myeloma related anemia. Med Hypotheses ,2006,66:352-354.
8Balogh A, Bosze S, Horvgtti K, et al. Role of iron metabolism- regulator hepcidin in perinatal iron homeostasis. Or,: Hefil,2010, 151:83-91.
9De Domenico I, Ward DM, Kaplan J, et al. Hepeidin and ferroportin: the new players in iron metabolism. Semin Liver Dis, 2011,31 : 272-279.
10Sharma S, Nemelh E, Chen YH, et at. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res ,2008,14:3262- 3267.
